Slate Path Capital LP Cyclerion Therapeutics, Inc. Transaction History

Slate Path Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	BUY	$2.18 - $4.29 $2.1 Million - $4.12 Million	961,538 Added 15.52%	7,157,601 $27.9 Million
Q3 2020 Nov 16, 2020	BUY	$3.46 - $8.39 $17.3 Million - $42 Million	5,000,000 Added 418.04%	6,196,063 $37.7 Million
Q1 2020 May 15, 2020	BUY	$2.46 - $5.84 $2.94 Million - $6.99 Million	1,196,063 New	1,196,063 $3.17 Million
Q4 2019 Feb 14, 2020	SELL	$1.8 - $13.43 $1.58 Million - $11.8 Million	-880,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.12 - $14.54 $1.35 Million - $2.41 Million	165,982 Added 23.25%	880,000 $10.7 Million
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $6.85 Million - $16.3 Million	714,018 New	714,018 $8.18 Million

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Slate Path Capital LP, based on Form 13F filings with the SEC.

Stay updated on Slate Path Capital LP with notifications on news.